At­se­na pri­or­i­tizes reti­nal gene ther­a­py pipeline, trims staff as ex­ist­ing in­vestors re­fu­el the biotech 

At­se­na Ther­a­peu­tics has re­duced its staff, is look­ing for a part­ner and has reeled in more cash from ex­ist­ing in­vestors, the gene ther­a­py biotech told …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.